A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma.
We have conducted a study of ilmofosine (1-hexadecylthio; 2-methoxyethyl-rac-glycero-3-phosphocholine) in non-small cell bronchogenic carcinoma, using a schedule of continuous infusion for 5 days and a dose of 300 mg/m2/day. Toxicities were gastrointestinal (nausea, vomiting, diarrhea), fatigue and liver function abnormalities. These were severe and resulted in the removal of some patients from study. No consistent pattern of bone marrow suppression was seen. No tumor regressions occurred in 14 evaluable patients including 5 with no prior therapy. We conclude that ilmofosine is inactive in this tumor at this dose and schedule.
Woolley
P V
PV
Laurel Highlands Cancer Program, Conemaugh's Memorial Medical Center, Lee Hospital, Johnstown, PA, USA.
Schultz
C J
CJ
Rodriguez
G I
GI
Gams
R A
RA
Rowe
K W
KW
Dadey
M L
ML
Von Hoff
D D
DD
McPhillips
J J
JJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010742:Phospholipid Ethers / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D010742:Phospholipid Ethers; C043297:ilmofosine